AN2 Therapeutics, Inc.

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics derived from its boron chemistry platform ¹. The company's development pipeline spans hematologic diseases, infectious diseases, and oncology, with three Phase 2 studies expected to initiate in 2026 and two preclinical candidates, alongside advanced research programs ². The company aims to deliver high-impact drugs addressing critical unmet needs and improving health outcomes ³.

The core business model revolves around the discovery and development of novel boron-based small-molecule therapeutics. Revenue generation is currently non-existent, as the company has no products approved for commercial sale and has incurred significant losses since its inception in 2017 ⁴. Operations are funded primarily through equity offerings and private placements ⁵. The company relies heavily on third-party contract manufacturers for raw materials, drug substance, and finished drug product for its preclinical and clinical trials ⁶. Its global health strategy leverages non-dilutive grant funding from public and private agencies and foundations to develop treatments for infectious diseases affecting underserved populations ⁷.

Epetraborole is a key product candidate with development plans in two distinct areas. In March 2026, the company announced plans to expand the development of oral epetraborole into a Phase 2 proof-of-concept clinical study for polycythemia vera (PV), a blood cancer affecting an estimated 155,000 people in the U.S. ⁸. This study is anticipated to initiate in India in Q3 2026, with data readouts expected from Q4 2026 through 2027 ⁹. The study aims to enroll approximately 40-50 patients across 3-5 or more sites ¹⁰. Additionally, in December 2025, the FDA cleared an Investigational New Drug Application (IND) for a Phase 2 investigator-initiated study (IIT) of epetraborole for Mycobacterium abscessus (M. abscessus) complex lung disease, a serious non-tuberculous mycobacterial infection with no FDA-approved treatments ¹¹. Enrollment for this study is expected to begin in Q1 2026, with topline results anticipated in late 2027 ¹². The company previously discontinued development of epetraborole for treatment-refractory MAC lung disease in May 2025, following the failure of the truncated Phase 3 portion of the EBO-301 study to meet its primary endpoint ¹³.

AN2-502998 is another significant product candidate, currently in a Phase 1 first-in-human trial for Chagas disease, an infectious disease affecting an estimated 6-10 million people worldwide ¹⁴. Initial clinical data for AN2-502998 is expected in Q1 2026, with a Phase 2 proof-of-concept trial in patients with chronic Chagas disease planned for 2026 ¹⁵. This compound has demonstrated curative activity in preclinical studies across multiple species, including nonhuman primates with naturally acquired chronic infections ¹⁶. FDA approval for Chagas disease, a designated tropical disease, could qualify the company for a priority review voucher ¹⁷.

The company's research and development initiatives also include oncology programs targeting PI3Kα and ENPP1, with plans to advance two candidates into development in 2026 ¹⁸. The PI3Kα program aims to develop a selective, pan-mutant inhibitor for activating mutations in PIK3Cα, which are common in various solid tumors, addressing limitations of existing inhibitors by targeting both kinase-domain and helical-domain mutations while maintaining selectivity over wild-type PI3Kα ¹⁹. The ENPP1 program focuses on inhibiting ectonucleotide pyrophosphatase/phosphodiesterase 1, an enzyme implicated in tumor immune evasion, with preclinical studies showing antitumor activity in murine models ²⁰. Global health programs, supported by non-dilutive grant funding, include melioidosis and tuberculosis, in partnership with the Gates Foundation and GSK ²¹. For melioidosis, discussions are underway with the U.S. government to fund Phase 2 development of epetraborole, with the aim of lowering the 90-day mortality rate which approaches 40% despite standard of care ²².

For the fiscal year ended December 31, 2025, the company reported a net loss of $35.2 million ²³, an improvement from a net loss of $51.3 million in 2024 ²⁴. Total operating expenses decreased to $38.1 million in 2025 from $56.8 million in 2024 ²⁵. Research and development expenses were $24.8 million in 2025, down from $40.5 million in 2024 ²⁶. General and administrative expenses were $13.3 million in 2025, compared to $14.1 million in 2024 ²⁷. Restructuring charges were zero in 2025, a decrease from $2.2 million in 2024 ²⁸. Interest income was $2.9 million in 2025, down from $5.5 million in 2024 ²⁹. As of December 31, 2025, the company had cash, cash equivalents, and investments of $60.0 million ³⁰, and an accumulated deficit of $241.0 million ³¹.

Year-over-year, research and development expenses decreased by $15.7 million ³², primarily due to a $12.8 million decrease in clinical trial expenses following the termination of the EBO-301 trial in August 2024, partially offset by the initiation of the Phase 1 Chagas disease trial ³³. Personnel-related expenses decreased by $4.3 million due to restructuring activities in 2024 ³⁴. Consulting and outside services expenses decreased by $2.3 million, and chemistry manufacturing and controls (CMC) expenses decreased by $1.3 million ³⁵. These decreases were partially offset by a $5.0 million increase in preclinical and research study expenses ³⁶. General and administrative expenses decreased by $0.8 million ³⁷.

Significant operational developments during the period include the discontinuation of epetraborole development for treatment-refractory MAC lung disease in May 2025, leading to a workforce reduction of approximately 50% in August 2024 ³⁸. The company also commenced its Phase 1 first-in-human trial of oral AN2-502998 for Chagas disease in August 2025 ³⁹ and received FDA clearance for a Phase 2 investigator-initiated study of epetraborole for M. abscessus lung disease in December 2025 ⁴⁰. In March 2026, the company announced a private placement generating aggregate gross proceeds of $40.0 million ⁴¹.

The company anticipates initiating three Phase 2 studies in 2026, including a Phase 2 proof-of-concept clinical study of oral epetraborole in adults with phlebotomy-dependent polycythemia vera (PV) in India in the third quarter of 2026 ⁴². Periodic data readouts for the PV study are expected to begin as early as the fourth quarter of 2026 and continue throughout 2027 ⁴³. Additionally, enrollment for the Phase 2 investigator-initiated study of epetraborole for Mycobacterium abscessus lung disease is expected to initiate in the first quarter of 2026, with topline results anticipated in late 2027 ⁴⁴. For AN2-502998 in Chagas disease, initial clinical data from the Phase 1 trial is expected in the first quarter of 2026, followed by the initiation of a Phase 2 proof-of-concept study in patients with chronic Chagas disease in 2026, contingent on the Phase 1 outcome and timing ⁴⁵.

A major growth area for the company is the expansion of epetraborole into new indications. The PV program targets approximately 155,000 people in the U.S. affected by this blood cancer, aiming to be the first oral, red-cell targeting therapy for hematocrit control, potentially offering competitive advantages in targeted effects, tolerability, and oral administration ⁴⁶. The M. abscessus lung disease program addresses a critical unmet need, as no FDA-approved drugs currently exist for this serious infection ⁴⁷. If approved, epetraborole would be positioned as the first FDA-approved drug for M. abscessus ⁴⁸.

Another significant growth vector is the advancement of AN2-502998 for Chagas disease. This compound is noted as the only one known to have demonstrated curative activity in preclinical studies across multiple species, including nonhuman primates with naturally acquired chronic infections, which may be more predictive of human efficacy ⁴⁹. There are no FDA-approved treatments for adults with chronic Chagas disease, and AN2-502998 has the potential to address unmet needs related to safety, efficacy, tolerability, and treatment burden ⁵⁰. FDA approval for Chagas disease, a tropical disease, would qualify the company for a priority review voucher, incentivizing development for neglected infectious diseases ⁵¹.

Operationally, the company expects its research and development expenses to increase substantially as it advances product candidates through clinical trials and regulatory approval, and as it seeks to discover and develop future product candidates ⁵². General and administrative expenses are also expected to increase due to legal, accounting, regulatory, and tax-related services associated with operating as a public company, as well as directors and officers liability insurance premiums and investor relations activities ⁵³. The company plans to continue using third-party service providers for preclinical, nonclinical, and clinical development, and for manufacturing and supply of materials ⁵⁴. If regulatory approval is obtained for any product candidates, the company intends to hire and deploy a specialty sales force, which will further increase operating costs ⁵⁵.

Regarding capital allocation, the company believes its existing cash, cash equivalents, and investments of $60.0 million as of December 31, 2025, will fund operating expenses and capital expenditure requirements for at least the next 12 months ⁵⁶. However, substantial additional funding will be required for continuing operations and planned activities, beyond the $40.0 million financing completed in March 2026 ⁵⁷. Future capital requirements will depend on factors such as the timing and results of clinical trials, regulatory review costs, manufacturing processes, and intellectual property maintenance ⁵⁸. The company's global health strategy relies on securing non-dilutive funding, such as grants and government contracts, to advance programs like melioidosis and tuberculosis ⁵⁹.

The company explicitly flags that its ability to generate product revenue depends on successful development, regulatory approval, and eventual commercialization of product candidates, which are uncertain events ⁶⁰. The research, development, manufacturing, and regulatory approval processes are long, expensive, and uncertain, with potential for delays or failures at any stage due to factors like toxicity, safety, tolerability, efficacy, or clinical trial enrollment issues ⁶¹. The company's limited operating history and experience in successfully completing pivotal clinical trials, obtaining regulatory approvals, or commercializing products are noted as challenges ⁶².

The company faces significant risks, including its status as a clinical-stage biopharmaceutical company with no approved products and a history of significant losses, with an accumulated deficit of $241.0 million as of December 31, 2025 ⁶³. There is substantial uncertainty in advancing its early-stage and mid-stage pipeline, as clinical proof of concept has not been established for any product candidates, and preclinical results may not translate to human studies ⁶⁴. The company requires substantial additional funding beyond its current cash, cash equivalents, and investments of $60.0 million as of December 31, 2025, and failure to raise capital could force delays or cessation of development programs ⁶⁵. Clinical trials may fail to demonstrate safety or efficacy, leading to increased costs or inability to complete development, as exemplified by the discontinuation of epetraborole for treatment-refractory MAC lung disease after the Phase 3 portion failed its primary endpoint ⁶⁶. Delays in patient enrollment, reliance on single-sourced third-party manufacturers and CROs, and the potential for undesirable side effects or drug resistance could also impede development and commercialization ⁶⁷. Even if approved, product candidates may not achieve market acceptance or adequate reimbursement from third-party payors ⁶⁸. The biopharmaceutical industry is intensely competitive, with many competitors possessing greater financial and technical resources ⁶⁹. The company's small team and dependence on key personnel, along with identified material weaknesses in internal control over financial reporting, pose operational risks ⁷⁰. Intellectual property protection is uncertain, with in-licensed patents potentially being challenged or expiring before commercialization, and the risk of third-party infringement claims ⁷¹. International operations expose the company to differing regulatory requirements, economic instability, and challenges in enforcing intellectual property rights ⁷². Changes in healthcare policies, such as the Inflation Reduction Act of 2022 and the One Big Beautiful Bill Act of July 2025, could negatively impact drug pricing and reimbursement ⁷³. Cybersecurity incidents and compliance with evolving data privacy laws also present material risks ⁷⁴.

Management's message emphasizes the company's commitment as a clinical-stage biopharmaceutical company to discover and develop novel small-molecule therapeutics using its boron chemistry platform, aiming to deliver high-impact drugs that address critical unmet needs and improve health outcomes ⁷⁵. They explicitly state that the company expects to incur significant expenses and operating losses over the next several years and anticipates needing substantial additional funding for its continuing operations and planned activities, beyond the $40.0 million in gross proceeds from the March 2026 Private Placement ⁷⁶. Key strategic priorities include advancing lead assets like epetraborole and AN2-502998 through Phase 2 and into later-stage studies, with a focus on demonstrating safety, efficacy, and a clear development path ⁷⁷. They also prioritize advancing and expanding the research pipeline by applying boron chemistry to discover and optimize new molecules in oncology, bone disorders, and infectious diseases, ensuring a sustainable flow of future product candidates ⁷⁸. Finally, management aims to leverage non-dilutive funding, such as grants and government contracts, to support global health programs like those for melioidosis and tuberculosis ⁷⁹.